Insider Selling: Heartflow (NASDAQ:HTFL) Insider Sells 9,219 Shares of Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 9,219 shares of Heartflow stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $28.34, for a total transaction of $261,266.46. Following the completion of the transaction, the insider owned 78,731 shares of the company’s stock, valued at $2,231,236.54. This represents a 10.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Campbell Rogers also recently made the following trade(s):

• On Wednesday, April 1st, Campbell Rogers sold 64,533 shares of Heartflow stock. The stock was sold at an average price of $24.64, for a total transaction of $1,590,093.12.
• On Thursday, March 19th, Campbell Rogers sold 64,533 shares of Heartflow stock. The stock was sold at an average price of $25.69, for a total transaction of $1,657,852.77.

Heartflow Stock Performance

HTFL stock traded up $0.78 during midday trading on Wednesday, reaching $27.38. 1,091,812 shares of the company were exchanged, compared to its average volume of 1,397,840. The company has a market cap of $2.36 billion and a price-to-earnings ratio of -8.80. Heartflow, Inc. has a 1-year low of $20.13 and a 1-year high of $41.22. The stock’s 50-day simple moving average is $27.37 and its 200 day simple moving average is $28.63.

Heartflow (NASDAQ:HTFL) last posted its earnings results on Thursday, May 14th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.08. The company had revenue of $52.59 million during the quarter. The company’s quarterly revenue was up 41.3% compared to the same quarter last year. On average, research analysts anticipate that Heartflow, Inc. will post -0.78 earnings per share for the current year.

Institutional Trading of Heartflow

Several institutional investors and hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP raised its position in Heartflow by 20.8% in the 4th quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock valued at $171,812,000 after purchasing an additional 1,014,006 shares during the last quarter. Baillie Gifford & Co. purchased a new stake in Heartflow in the 3rd quarter valued at $101,182,000. Bamco Inc. NY raised its position in Heartflow by 86.2% in the 4th quarter. Bamco Inc. NY now owns 2,303,877 shares of the company’s stock valued at $67,158,000 after purchasing an additional 1,066,371 shares during the last quarter. Janus Henderson Group PLC raised its position in Heartflow by 152.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock valued at $53,063,000 after purchasing an additional 1,315,416 shares during the last quarter. Finally, Schusterman Interests LLC purchased a new stake in Heartflow in the 3rd quarter valued at $65,274,000.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Wells Fargo & Company increased their target price on shares of Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. William Blair assumed coverage on shares of Heartflow in a research report on Monday, May 4th. They issued an “outperform” rating on the stock. Canaccord Genuity Group dropped their target price on shares of Heartflow from $43.00 to $37.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, March 19th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.00.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.